Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung bipolarer Störungen

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5193 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Stimmungsstabilisierer im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der Darstellung des Risikos der Antidepressiva bei der Verordnung bei der bipolaren Depression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amsterdam JD, Lorenzo-Luaces L, Soeller I et al (2015) Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 185: 31–37

    Google Scholar 

  • Armani F, Andersen ML, Galduróz JC (2014) Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology (Berl) 231(4): 639–649

    Google Scholar 

  • Bowden CL, Singh V, Weisler R (2012) Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 126(5): 342–350

    Google Scholar 

  • Cipriani A, Barbui C, Salanti G et al (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378(9799): 1306–1315

    Google Scholar 

  • Cipriani A, Reid K, Young AH et al (2013) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 10: CD003196

    Google Scholar 

  • Crump C, Sundquist K, Winkleby MA et al (2013) Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70(9): 931–939

    Google Scholar 

  • DGBS e.V., DGPPN e.V. (2012) S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0, Mai 2012

    Google Scholar 

  • Ducasse D, Jaussent I, Guillaume S et al (2015) Increased risk of suicide attempt in bipolar patients with severe tobacco dependence. J Affect Disord 183: 113–118

    Google Scholar 

  • El-Mallakh RS, Vöhringer PA, Ostacher MM et al (2015) Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord 184: 318–321

    Google Scholar 

  • Fountoulakis KN, Kasper S, Andreassen O et al (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262(Suppl 1): 1–48

    Google Scholar 

  • Frye MA, Amchin J, Bauer M et al (2015) Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord 3(1): 34

    Google Scholar 

  • Geddes JR, Gardiner A, Rendell J et al (2016) Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3(1): 31–39

    Google Scholar 

  • Gerhard T, Devanand DP, Huang C et al (2015) Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry 207(1): 46–51

    Google Scholar 

  • Ghaemi SN, Ostacher MM, El-Mallakh RS et al (2010) Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71(4): 372–380

    Google Scholar 

  • Goss AJ, Kaser M, Costafreda SG et al (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74(11): 1101–1107

    Google Scholar 

  • Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2): 94–112

    Google Scholar 

  • Grunze H, Vieta E, Goodwin GM et al (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3): 154–219

    Google Scholar 

  • Hou L, Heilbronner U, Degenhardt F et al (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet pii: S0140–6736(16)00143-4

    Google Scholar 

  • Kessing LV, Vradi E, Andersen PK (2014) Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 205(3): 214–220

    Google Scholar 

  • Kessing LV, Gerds TA, Feldt-Rasmussen B et al (2015) Lithium and renal and upper urinary tract tumors – results from a nationwide population-based study. Bipolar Disord 17(8): 805–813

    Google Scholar 

  • Ketter TA, Miller S, Dell’Osso B, Wang PW (2016) Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 191: 256–273

    Google Scholar 

  • Leon AC, Solomon DA, Li C et al (2012) Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 169(3): 285–291

    Google Scholar 

  • Li CT, Bai YM, Huang YL et al (2012) Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 200(1): 45–51

    Google Scholar 

  • Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ (2016) Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 133(6): 459–469

    Google Scholar 

  • McCloud TL, Caddy C, Jochim J et al (2015) Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 9: CD011611

    Google Scholar 

  • McIntyre RS, McElroy SL, Eudicone JM et al (2011) A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord 13(6)

    Google Scholar 

  • McKnight RF, Adida M, Budge K (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379(9817): 721–728

    Google Scholar 

  • Merikangas KR, Jin R, He JP et al (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3): 241–251

    Google Scholar 

  • Miura T, Noma H, Furukawa TA et al (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1(5): 351–359

    Google Scholar 

  • Naughton M, Clarke G, O’Leary OF et al (2014) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156: 24–35

    Google Scholar 

  • Pacchiarotti I, Bond DJ, Baldessarini RJ et al (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170(11): 1249–1262

    Google Scholar 

  • Parikh SV, LeBlanc SR, Ovanessian MM (2010) Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can J Psychiatry 55(3): 136–143

    Google Scholar 

  • Post RM, Leverich GS, Altshuler LL et al (2012) Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry. 73(7): 924–930

    Google Scholar 

  • Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386(9992): 461–468

    Google Scholar 

  • Stubbs B, Eggermont L, Mitchell AJ et al (2015) The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand 131(2): 75–88

    Google Scholar 

  • Tohen M, McIntyre RS, Kanba S et al (2014) Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord 168: 136–141

    Google Scholar 

  • Viktorin A, Lichtenstein P, Thase ME et al (2014) The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. doi: 10.1176/appi.ajp.2014.13111501

  • Vöhringer PA, Ostacher MJ, El-Mallakh RS et al (2015) Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. J Clin Psychopharmacol 35(5): 605–508

    Google Scholar 

  • Yatham LN, Fountoulakis KN, Rahman Z et al (2013) Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 147(1–3): 365–372

    Google Scholar 

  • Yildiz A, Nikodem M, Vieta E et al (2015) A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 45(2): 299–317

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aachen

    Dr. med. Dipl.-Kaufm. M. Paulzen & Prof. Dr. med. G. Gründer

  2. Mainz

    Prof. Dr. med. O. Benkert

Authors
  1. Dr. med. Dipl.-Kaufm. M. Paulzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. G. Gründer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mainz

    Otto Benkert

  2. München

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Paulzen, M., Gründer, G., Benkert, O. (2017). Medikamente zur Behandlung bipolarer Störungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation